MALAT1 and prostate carcinoma: Conclusively, our mice xenograft studies showed that olaparib-mediated reduction of prostate tumor growth and metastases is potentiated by inhibition of MALAT1. These findings suggest that targeting MALAT1 enhances the vulnerability of prostate cancer to PARPi therapy.